Clinical relevance of immune checkpoints on circulating tumor cells in breast cancer
MA Papadaki, AV Koutsopoulos, PG Tsoulfas… - Cancers, 2020 - mdpi.com
The role of CD47 and PD-L1 expression on circulating tumor cells (CTCs) remains unclear,
and it is currently unknown whether their distribution varies between the blood and tumor …
and it is currently unknown whether their distribution varies between the blood and tumor …
The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients
T Reinert, FO do Rego, MC e Silva… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Background Breast cancer is the leading cause of cancer death among women worldwide.
Studies about the genomic landscape of metastatic breast cancer (MBC) have …
Studies about the genomic landscape of metastatic breast cancer (MBC) have …
Genomic characterization of de novo metastatic breast cancer
S Mullangi, N Vasan - Clinical breast cancer, 2022 - Elsevier
De novo metastatic breast cancer (dnMBC) represents a minority of MBC cases, and as
such, its genomics are poorly understood. Characterizing the genomics of dnMBC …
such, its genomics are poorly understood. Characterizing the genomics of dnMBC …
Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer
Endocrine therapy with or without CDK4/6 inhibitors is the most commonly used frontline
treatment option for metastatic hormone receptor–positive breast cancer. Approximately …
treatment option for metastatic hormone receptor–positive breast cancer. Approximately …
[PDF][PDF] Highlights in breast cancer
MJ Piccart-Gebhart - ariez.nl
The CTS-5 clinical score, developed by the Royal Marsden hospital and based on patient
age as well as tumor grade/size and nodal status, has now been validated in disease-free …
age as well as tumor grade/size and nodal status, has now been validated in disease-free …